Abstract: The present invention provides a technology for performing a test for prostate cancer. This method is for testing the possibility of having prostate cancer, the method comprising (1) measuring the amount or concentration of a biomarker in a body fluid sample collected from a subject, the biomarker being at least one member selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl) phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone.

Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.